| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1517/14712590903514090 |
| P698 | PubMed publication ID | 20001562 |
| P2093 | author name string | Don Dizon | |
| Katrin Kristjansdottir | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab | Q27640593 | ||
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| Cancer statistics, 2008 | Q27860585 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer | Q29617440 | ||
| Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex | Q34314489 | ||
| The epidermal growth factor receptor: a new target for anticancer therapy | Q34708232 | ||
| HER2 therapy: molecular mechanisms of trastuzumab resistance. | Q35633712 | ||
| New targeted approaches in chronic myeloid leukemia | Q36254592 | ||
| HER dimerization inhibitors: developing pertuzumab as an anticancer agent in women's oncology | Q38089883 | ||
| Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity. | Q39802073 | ||
| Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab | Q39840667 | ||
| Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo | Q39865068 | ||
| Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy | Q40138970 | ||
| Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells | Q40344963 | ||
| The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. | Q40571024 | ||
| Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth | Q43619428 | ||
| Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth | Q44120544 | ||
| Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy | Q46610633 | ||
| Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status | Q57217085 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pertuzumab | Q1998021 |
| P304 | page(s) | 243-250 | |
| P577 | publication date | 2010-02-01 | |
| P1433 | published in | Expert Opinion on Biological Therapy | Q5421201 |
| P1476 | title | HER-dimerization inhibitors: evaluating pertuzumab in women's cancers | |
| P478 | volume | 10 |
| Q47158524 | A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer |
| Q35479646 | ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis |
| Q42050622 | Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery? |
| Q36385800 | Multi-parametric analysis reveals enhanced G2-phase arrest of an optimized anti-HER2 antibody to inhibit breast cancer |
| Q37155964 | New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches. |
| Q37687975 | Precision medicine and personalized breast cancer: combination pertuzumab therapy |
| Q34054213 | The role of HER2 in cancer therapy and targeted drug delivery |
| Q34719632 | Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies |
Search more.